Loading...

You're on the old version of Simply Wall St. We will no longer be supporting this site, so we recommend you switch to our brand new platform.

EirGenix

GTSM:6589
Snowflake Description

Imperfect balance sheet with limited growth.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
6589
GTSM
NT$5B
Market Cap
  1. Home
  2. TW
  3. Pharmaceuticals & Biotech
Company description

EirGenix Inc. operates as a contract development and manufacturing company worldwide. The last earnings update was 2 days ago. More info.


Add to Portfolio Compare Print
  • EirGenix has significant price volatility in the past 3 months.
6589 Share Price and Events
7 Day Returns
10.9%
GTSM:6589
4.5%
Asia Life Sciences
8.4%
TW Market
1 Year Returns
-28.2%
GTSM:6589
22.2%
Asia Life Sciences
-10.6%
TW Market
6589 Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
EirGenix (6589) 10.9% -4.8% 2% -28.2% -26.3% -
Asia Life Sciences 4.5% -10.9% -1.4% 22.2% 103.8% 65.6%
TW Market 8.4% -14.9% -19.9% -10.6% -3.9% -0.8%
1 Year Return vs Industry and Market
  • 6589 underperformed the Life Sciences industry which returned 22.2% over the past year.
  • 6589 underperformed the Market in Taiwan, Province of China which returned -10.6% over the past year.
Price Volatility
6589
Industry
5yr Volatility vs Market

Value

 Is EirGenix undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for EirGenix. This is due to cash flow or dividend data being unavailable. The share price is NT$28.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for EirGenix's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are EirGenix's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
GTSM:6589 PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-12-31) in TWD NT$-5.39
GTSM:6589 Share Price ** GTSM (2020-03-31) in TWD NT$28
Asia Life Sciences Industry PE Ratio Median Figure of 45 Publicly-Listed Life Sciences Companies 37.75x
Taiwan, Province of China Market PE Ratio Median Figure of 1,466 Publicly-Listed Companies 13.66x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of EirGenix.

GTSM:6589 PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= GTSM:6589 Share Price ÷ EPS (both in TWD)

= 28 ÷ -5.39

-5.19x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • EirGenix is loss making, we can't compare its value to the Asia Life Sciences industry average.
  • EirGenix is loss making, we can't compare the value of its earnings to the Taiwan, Province of China market.
Price based on expected Growth
Does EirGenix's expected growth come at a high price?
Raw Data
GTSM:6589 PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -5.19x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 1 Analysts
11.8%per year
Asia Life Sciences Industry PEG Ratio Median Figure of 19 Publicly-Listed Life Sciences Companies 1.46x
Taiwan, Province of China Market PEG Ratio Median Figure of 196 Publicly-Listed Companies 1.01x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for EirGenix, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on EirGenix's assets?
Raw Data
GTSM:6589 PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-12-31) in TWD NT$10.92
GTSM:6589 Share Price * GTSM (2020-03-31) in TWD NT$28
Asia Life Sciences Industry PB Ratio Median Figure of 68 Publicly-Listed Life Sciences Companies 3.13x
Taiwan, Province of China Market PB Ratio Median Figure of 1,963 Publicly-Listed Companies 1.16x
GTSM:6589 PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= GTSM:6589 Share Price ÷ Book Value per Share (both in TWD)

= 28 ÷ 10.92

2.56x

* Primary Listing of EirGenix.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • EirGenix is good value based on assets compared to the Asia Life Sciences industry average.
X
Value checks
We assess EirGenix's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Life Sciences industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Life Sciences industry average (and greater than 0)? (1 check)
  5. EirGenix has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is EirGenix expected to perform in the next 1 to 3 years based on estimates from 1 analyst?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
11.8%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is EirGenix expected to grow at an attractive rate?
  • Unable to compare EirGenix's earnings growth to the low risk savings rate as it is expected to be loss making during the next 1-3 years.
Growth vs Market Checks
  • Unable to compare EirGenix's earnings growth to the Taiwan, Province of China market average as it is expected to be loss making during the next 1-3 years.
  • EirGenix's revenue growth is expected to exceed the Taiwan, Province of China market average.
Annual Growth Rates Comparison
Raw Data
GTSM:6589 Future Growth Rates Data Sources
Data Point Source Value (per year)
GTSM:6589 Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 1 Analysts 11.8%
GTSM:6589 Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 1 Analysts 52.8%
Asia Life Sciences Industry Earnings Growth Rate Market Cap Weighted Average 29.7%
Asia Life Sciences Industry Revenue Growth Rate Market Cap Weighted Average 22.2%
Taiwan, Province of China Market Earnings Growth Rate Market Cap Weighted Average 11.2%
Taiwan, Province of China Market Revenue Growth Rate Market Cap Weighted Average 7%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
GTSM:6589 Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below
All numbers in TWD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
GTSM:6589 Future Estimates Data
Date (Data in TWD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2021-12-31 1,488 -671 -643 1
2020-12-31 907 -1,192 -1,249 1
2020-03-31
GTSM:6589 Past Financials Data
Date (Data in TWD Millions) Revenue Cash Flow Net Income *
2019-12-31 476 -784 -861
2019-09-30 395 -652 -681
2019-06-30 365 -546 -475
2019-03-31 288 -605 -414
2018-12-31 282 -466 -368
2018-09-30 295 -391 -304
2018-06-30 330 -313 -251
2018-03-31 315 -230 -229
2017-12-31 298 -190 -175
2017-09-30 281 -196 -172
2017-06-30 258 -183 -167
2017-03-31 256 -119 -140

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • EirGenix is not considered high growth as it is expected to be loss making for the next 1-3 years.
  • EirGenix's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
GTSM:6589 Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below

All data from EirGenix Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

GTSM:6589 Future Estimates Data
Date (Data in TWD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2021-12-31 -3.15 -3.15 -3.15 1.00
2020-12-31 -6.39 -6.39 -6.39 1.00
2020-03-31
GTSM:6589 Past Financials Data
Date (Data in TWD Millions) EPS *
2019-12-31 -5.39
2019-09-30 -4.47
2019-06-30 -3.36
2019-03-31 -3.07
2018-12-31 -2.97
2018-09-30 -2.66
2018-06-30 -2.30
2018-03-31 -2.20
2017-12-31 -1.70
2017-09-30 -1.67
2017-06-30 -1.63
2017-03-31 -1.40

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if EirGenix will efficiently use shareholders’ funds in the future (Return on Equity greater than 20%) as it is not expected to be profitable.
X
Future performance checks
We assess EirGenix's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Asia market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Asia market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
EirGenix has a total score of 2/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has EirGenix performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare EirGenix's growth in the last year to its industry (Life Sciences).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • EirGenix does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare EirGenix's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare EirGenix's 1-year growth to the Asia Life Sciences industry average as it is not currently profitable.
Earnings and Revenue History
EirGenix's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from EirGenix Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

GTSM:6589 Past Revenue, Cash Flow and Net Income Data
Date (Data in TWD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-12-31 476.09 -860.93 142.73 959.61
2019-09-30 395.17 -681.37 140.67 738.34
2019-06-30 365.18 -475.04 134.32 527.91
2019-03-31 288.36 -413.59 123.33 408.25
2018-12-31 282.21 -367.79 111.50 344.20
2018-09-30 295.28 -304.15 100.37 303.91
2018-06-30 329.79 -250.62 93.24 285.52
2018-03-31 315.02 -228.54 91.09 255.61
2017-12-31 297.87 -174.86 90.90 199.35
2017-09-30 281.29 -171.92 88.39 187.84
2017-06-30 258.48 -167.07 86.05 174.60
2017-03-31 255.80 -139.74 80.33 162.45
2016-12-31 253.11 -112.41 74.60 150.30
2016-09-30 214.70 -109.55 73.10 129.26
2016-06-30 176.30 -106.69 71.59 108.22
2016-03-31 139.54 -120.64 69.05 103.67
2015-12-31 102.78 -134.58 66.50 99.11
2014-12-31 53.80 -132.94 43.46 86.55
2013-12-31 8.58 -104.79 23.61 40.51

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if EirGenix has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if EirGenix has efficiently used its assets last year compared to the Asia Life Sciences industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if EirGenix improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess EirGenix's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Life Sciences industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
EirGenix has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is EirGenix's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up EirGenix's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • EirGenix is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • EirGenix's long term commitments exceed its cash and other short term assets.
Balance sheet
This treemap shows a more detailed breakdown of EirGenix's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • High level of physical assets or inventory.
  • Debt is covered by short term assets, assets are 1.6x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from EirGenix Company Filings, last reported 3 months ago.

GTSM:6589 Past Debt and Equity Data
Date (Data in TWD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-12-31 1,854.87 647.13 292.33
2019-09-30 2,134.93 786.50 626.11
2019-06-30 2,434.77 786.23 966.95
2019-03-31 1,945.62 716.61 521.00
2018-12-31 2,087.71 667.35 872.75
2018-09-30 1,406.02 546.28 507.82
2018-06-30 1,480.32 418.03 664.60
2018-03-31 1,144.81 207.52 572.04
2017-12-31 1,144.81 207.52 572.04
2017-09-30
2017-06-30 1,217.54 30.23 718.76
2017-03-31 1,217.54 30.23 718.76
2016-12-31 1,305.67 0.00 930.48
2016-09-30 1,305.67 0.00 930.48
2016-06-30 1,369.27 0.00 1,024.57
2016-03-31 1,369.27 0.00 1,024.57
2015-12-31 705.56 0.00 378.77
2014-12-31 806.19 0.00 572.06
2013-12-31 439.13 30.00 287.72
  • EirGenix's level of debt (34.9%) compared to net worth is satisfactory (less than 40%).
  • Unable to establish if EirGenix's debt level has increased without past 5-year debt data.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • EirGenix has less than a year of cash runway based on current free cash flow.
  • EirGenix has less than a year of cash runway if free cash flow continues to grow at historical rates of 43% each year.
X
Financial health checks
We assess EirGenix's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. EirGenix has a total score of 2/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is EirGenix's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from EirGenix dividends.
If you bought NT$2,000 of EirGenix shares you are expected to receive NT$0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate EirGenix's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate EirGenix's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
GTSM:6589 Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below
Asia Life Sciences Industry Average Dividend Yield Market Cap Weighted Average of 21 Stocks 0.5%
Taiwan, Province of China Market Average Dividend Yield Market Cap Weighted Average of 1331 Stocks 4.6%
Taiwan, Province of China Minimum Threshold Dividend Yield 10th Percentile 1.8%
Taiwan, Province of China Bottom 25% Dividend Yield 25th Percentile 3.3%
Taiwan, Province of China Top 25% Dividend Yield 75th Percentile 7.1%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

GTSM:6589 Future Dividends Estimate Data
Date (Data in NT$) Dividend per Share (annual) Avg. No. Analysts
2021-12-31
2020-12-31
2020-03-31

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as EirGenix has not reported any payouts.
  • Unable to verify if EirGenix's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of EirGenix's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as EirGenix has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess EirGenix's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can EirGenix afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. EirGenix has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of EirGenix's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Cheng Lee
CEO Bio

Dr. Cheng Liu Lee serves as Chief Executive Officer and President of EirGenix Inc. Dr. Lee has 30 years of product, process development and manufacturing experience in biotech, pharmaceutical and specialty chemical industries. Prior to returning Taiwan to start up EirGenix, Dr. Lee was the President and Chief Operating Officer of AnGes Inc., a late developmental stage biotech enterprise. He joined AnGes in 2002 as a Vice President of Product Management. He also served as a Vice Chairman in the Supervisory Board of Avontec GmbH, a Munich based joint venture with AnGes, from 2004 to 2010. Before his tenure with AnGes, he served various management and professional positions to lead product/process development at GenVec, Novartis, W.R.Grace & Co. and Halcon SD. Dr. Lee holds a doctorial degree in Chemical Engineering & Applied Chemistry from Columbia University and a BS degree in Chemical Engineering from National Taiwan University.

CEO Compensation
  • Insufficient data for Cheng to compare compensation growth.
  • Insufficient data for Cheng to establish whether their remuneration is reasonable compared to companies of similar size in Taiwan, Province of China.
Management Team Tenure

Average tenure of the EirGenix management team in years:

1.2
Average Tenure
  • The average tenure for the EirGenix management team is less than 2 years, this suggests a new team.
Management Team

Cheng Lee

TITLE
CEO & President

Hsiu Chuan Yang

TITLE
VP & CFO
TENURE
1.2 yrs

Chih-Jung Chang

TITLE
VP & COO
TENURE
1.2 yrs

Ping Yang Yeh

TITLE
VP & CTO
TENURE
1.2 yrs

Thomas Schulze

TITLE
Managing Director of EirGenix Europe GmbH

Irene Lin

TITLE
Executive Director of Analytical Science and Quality Control

Shang-Chung Ju

TITLE
Executive Director of Manufacturing and Engineering Operation
Board of Directors
Who owns this company?
Recent Insider Trading
  • No 3 month open market individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (NT$) Value (NT$)
X
Management checks
We assess EirGenix's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. EirGenix has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

EirGenix Inc. operates as a contract development and manufacturing company worldwide. Its services include cell line development and cell bank manufacturing, process development, analytical sciences and quality control, cGMP manufacturing, and antibody drug conjugate. EirGenix Inc. was founded in 2012 and is based in New Taipei City, Taiwan.

Details
Name: EirGenix Inc.
6589
Exchange: GTSM
Founded: 2012
NT$4,739,952,000
169,284,000
Website: http://www.eirgenix.com
Address: EirGenix Inc.
No. 101, Kangning Street,
Lane 169,
New Taipei City,
22180,
Taiwan
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
GTSM 6589 Common Shares Taipei Exchange TW TWD 23. Nov 2016
Number of employees
Current staff
Staff numbers
179
EirGenix employees.
Industry
Life Sciences Tools and Services
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2020/03/31 17:16
End of day share price update: 2020/03/31 00:00
Last estimates confirmation: 2020/03/29
Last earnings filing: 2020/03/29
Last earnings reported: 2019/12/31
Last annual earnings reported: 2019/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.